Clinicians should consult literature so treatment options are current

Article

If the diploma on your office wall isn't freshly minted, chances are many of the decisions you make every day are based on outdated information from your optometry school classes.

Atlanta-If the diploma on your office wall isn't freshly minted, chances are many of the decisions you make every day are based on outdated information from your optometry school classes.

"There are a number of things we were taught during our training that, on reflection and further study, we find are no longer true or were never true, but rather based upon opinion and not fact," said Joseph Sowka, OD, FAAO, Diplomate, at the SECO meeting.

Myth: Dilate blood pressure patients

For example, clinicians have long been hesitant to dilate patients with markedly elevated blood pressure, particularly using an agent such as phenylephrine. The fear was that the drug, even at a low concentration of 2.5%, would further elevate blood pressure and put patients at risk of a cardiac event, Dr. Sowka said.

"There's never been any support behind this concept," he added. "When you look in the literature, there have been no adverse effects to patients using this agent at this concentration."

Myth: Dilating pregnant patients

Clinicians are also concerned about dilating patients who are pregnant or nursing. Their unease is due to the fear of teratogenic effects to the unborn child or the possibility of toxicity or other life-threatening effects to the newborn.

"When risks are outweighed by benefits of either dilation or therapeusis, this sometimes needs to be done," Dr. Sowka added. "But it should be done with informed consent from the patient and possibly in consult with the obstetrician."

He said that the highest potential for teratogenicity to the fetus is in the first trimester.

Recent Videos
EnVision Summit Cochair Cecelia Koetting, OD, FAAO, Dipl ABO, says that attendees should get ready for more discussion-based panels at this year's conference.
From contact lens dropout to addressing diabetic retinopathy in rural communities, optometrists choose an area of eye care research that they would expand, given the appropriate resources.
Bonnie An Henderson in an interview for the EnVision Summit
From new treatments on the horizon for macular degeneration to strengthening comanagement ties, optometrists cite a lot to be excited about in the coming year.
EnVision Summit cofounder and program chair Dr Bonnie Henderson chats about collaborative eye care
Practice owners testify to the importance of trying new things, not being afraid to fail, and utilizing community as a resource when starting up a new practice.
Bonnie An Henderson in an interview for the EnVision Summit
Optometrists reflect on their residency experiences and provide advice to current residents.
EnVision Summit Co-chairs Sherrol Reynolds, OD, FAAO; Katie Rachon, OD, FAAO, Dipl ABO; Jessica Steen, OD, FAAO, Dipl ABO; and Cecelia Koetting, OD, FAAO, Dipl ABO; express excitement for the upcoming conference and why optometrists should attend.
© 2025 MJH Life Sciences

All rights reserved.